Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see a ...
Gritstone also has a vaccine for KRAS-driven tumors in Phase 2 development. The company is also developing an HIV vaccine with Gilead Sciences ( GILD ), according to its website. More on Gritstone bio ...
Gritstone's candidate is a self-amplifying messenger RNA vaccine (samRNA), which uses a slightly different technology to the mRNA-based jabs from Pfizer/BioNTech and Moderna.
Gritstone bio ( NASDAQ:GRTS ) Second Quarter 2024 Results Key Financial Results Revenue: US$921.0k (down 53% from 2Q... -- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
The University of Sheffield is one of the best universities in the country for working with businesses and public and ...
EMERYVILLE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Northern Gritstone, the new investment business focused on university spin-outs in the north of England, today announces a first close of £215m having seen strong interest from investors in its ...
Gritstone Bio GRTS has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of ...
Fundraise includes over £150m from local and regional authority pension funds This will be deployed to back science and technology firms in the North of England Builds on momentum of 15 initial ...